pp-064 Cutaneous ointment
Dossier type
US CTD
Dossier status
Under development
Country of origin
Canada
Comments
Indication: Allergic contact dermatitis, targeting inflammatory skin responses driven by lipid-mediated activation pathways.
Clinical stage: Phase 2 clinical development.
Modality: Small-molecule sPLA2 inhibitor
Mechanism / Target: Inhibits secretory phospholipase A2 to reduce production of pro-inflammatory lipid mediators responsible for acute and chronic dermatitis reactions.
Route / form: Topical formulation
Differentiation: Steroid-free anti-inflammatory therapeutic offering potential for effective treatment without corticosteroid-associated side effects; designed for improved safety in recurrent or chronic dermatitis.
Manufacturer #38616
A clinical-stage biopharmaceutical company developing innovative therapies for inflammatory and immune-related diseases, with a focus on dermatology and serious respiratory conditions. It advances host-directed biologics and small molecule programs through global clinical studies and strategic partnerships. The organization targets unmet needs with novel mechanisms beyond standard treatments.